Corona Remedies Limited is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing, and marketing products across women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty therapeutics. The Company is among the fastest growing pharmaceutical players in the Indian Pharmaceutical Market (IPM), consistently outperforming industry growth across key therapeutic areas.

Market Position and Growth Leadership

According to the CRISIL Intelligence Report, Corona Remedies is:

– The fastest-growing company among the top 30 IPM players based on domestic sales growth (MAT June 2024 – MAT June 2025), with a CAGR of 13.58%, nearly 2x the IPM growth.

– The second fastest-growing company among the top 30 between MAT June 2022 and MAT June 2025, with domestic sales CAGR of 16.77%, against the IPM’s 9.21%.

– A company with superior growth fueled by higher volume expansion (5.70% vs IPM’s 2.15%) and strong new product launches (4.57% vs IPM’s 1.74%).

The Company’s focus on chronic and sub-chronic therapies strengthened its market positioning, with these categories contributing 70.10% of domestic sales, significantly outperforming IPM growth.

Diverse Product Portfolio and Brand Leadership

Corona Remedies markets 71 brands across key therapies. Its 27 “engine brands” contribute 72.34% of domestic sales (MAT June 2025) and include market leaders such as Cor, Trazer, Cor9, B-29, and Myoril. Many brands hold #1 rankings in their respective IPM sub-groups, reflecting strong brand equity and consistent prescription demand.

The Company offers comprehensive product coverage in Women’s healthcare (adolescence to menopause), Cardio-diabeto (from pre-diabetes to complications management), Pain management (tablets, capsules, sprays, injections) and Urology (BPH, OAB, UTIs, renal stones).

Strategic Focus on the “Middle of the Pyramid”

Corona Remedies targets specialist and super-specialist doctors across urban and semi-urban India—the fastest-growing segment in the pharmaceutical ecosystem.

– 75.75% of prescriptions come from specialists (vs 60.96% for IPM).
– The Company has improved its IPM ranking from #37 to #29 between MAT June 2022 and MAT June 2025.
– It is the 17th largest player within its covered markets and the third fastest-growing Indian pharma company in targeted specialties.

With 2,671 medical representatives across 22 states, the Company has strong reach and deep engagement capabilities with physicians and hospitals.